Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 10/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.93 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.93 |
| ▸ | GLA | P06280 | 3/20 | 0.93 |
| ▸ | GAA | P10253 | 3/20 | 0.93 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.93 |
| ▸ | MAPT | P10636 | 3/20 | 0.93 |
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.93 |
| ▸ | HPGD | P15428 | 2/20 | 0.93 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.93 |
| ▸ | NPC1 | O15118 | 2/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.93 |
| ▸ | RAB9A | P51151 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prazosin SCHEMBL29376126 | 0.96 | ADRA1B (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL26524 | 0.96 | ADRA1B (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL1172954 | 0.95 | ADRA1B (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL611396 | 0.95 | ADRA1B (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL29908896 | 0.95 | ADRA1B (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL41257 | 0.95 | ADRA1B (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL11656542 | 0.94 | KDM4E (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL9663302 | 0.94 | KDM4E (1.00) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL41258 | 0.94 | ADRA1B (0.96) | ADRA1BADRA1AADRA1DKDM4EGLA | |
| Prazosin SCHEMBL29157754 | 0.94 | ADRA1A (0.94) | ADRA1BADRA1AADRA1DKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| EP-0461681-B1 | Use of quinazolines in the preparation of a medicament for treating and preventing arrhythmia | EISAI CO LTD (JP) | 1995-04-26 | — | — | EP | disclosed |
| EP-0461681-A2 | Use of quinazolines in the preparation of a medicament for treating and preventing arrhythmia | Eisai Co., Ltd. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4707477-A | Treating and preventing agent for ischemic cardiac disease and arrhythmia | EISAI CO., LTD. (JP) | 1987-11-17 | — | — | US | disclosed |
| EP-0209089-A2 | Use of quinazolines in the preparation of a medicament for treating and preventing ischemic cardiac disease or arrhythmia | Eisai Co., Ltd. (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | ADRA1B 3799/4885ADRA1A 3531/4885ADRA1D 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.